{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/contentassets/5e6e95b92c1a4d82889b044224aeb360/2019-arlig-driftsrapport-for-helseregistre-ved-fhi.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "-Sofie Furberg , NORM, UNN Register for resistensoverv\u00e5kning av virus i Norge (RAVN) 2019 2019 Anne - myndighetsforhold 11 2.3 Juridiske rammer 12 2.4 Andre f\u00f8ringer 13 13 3 Definisjoner 6 registre Innsynsforesp\u00f8rsler registre Innsynsforesp\u00f8rsler av 105 113 11.4.2 Vedlegg 2. Oppsummering av drifts\u00e5ret for NORM 114 12 Resistensoverv\u00e5kning av virus i Norge (RAVN) ________________________________ ________ av 118 opplysninger om hendelsen er helseregister med data om de samm e * 15 638 96 15 734 0,6 14 033 NA 2016 41+9 spesialister 14 268 181 14 449 1,3 13 192 2017 41+8 spesialister* 14 152 246 14 398 1,7 12 749 NA 2018 41 13 663 4 13 667 0,03 12 390 NA 2019 41 13 094 5 13 099 0,04 11 726 NA *Prosjekt 797 781 Lav 2016 14 604 14 589 99,9 Lav 2017 13 920 12 246 1 654 13 900 99,9 Lav 2018 13 666 11 478 2 170 13 648 99,9 Lav 2019 12 940 11 421 1 509 12 930 99,9 Lav 15 781 2016 14 589 2017 13 900 1 681 12 1 859 13 722 98,7 2018 13 648 990 7,3 1 148 13 490 98,8 2019 12 930 1 283 9,9 1 478 12 735 98,5 Total vurdering av korrekthet g) 2015 NA NA NA Ja Ja Ja Medium 2016 NA NA NA Ja Ja Ja Medium 2017 NA NA NA Ja Nei Ja Medium 2018 NA NA NA Ja Ja Ja Medium 2019 NA NA NA Ja Ja Ja Medium Kommentarer: a) Meldingene til Abortregisteret er avidentifiserte, og data andre registre. b) til Abortregisteret data andre registre. c) til og data uker/mnd. a) Tid av til endelige statistikkbank 2015 Nei Nei Nei Ja 2016 Nei Nei Nei Ja 2017 Nei Nei Nei Ja 2018 Nei Nei Nei Ja 2019 Nei Nei Nei Ja Kommentarer: I statistikkbanken finnes statistikk om alle siste Den omfatter standardtabellverk. NA NA NA 0 6 NA 100,0 2016 NA NA 1 NA 0 7 NA 100,0 2017 NA NA NA NA 3 12 NA 100,0 2018 NA NA 1 NA 3 14 NA 100,0 2019 NA NA 0 NA 3 9 NA 100,0 Kommentarer: Periodiske rapporter: Driftsrapport helseregistrene 2019 Folkehelseinstituttet 20 1. Nordisk abortstatistikk - National Institute for Health and Welfare 2. Data til Norgeshelsa/Kommunehelsa og Folkehelserapporten b) 2015 NA NA 2016 NA NA 2017 NA NA 2018 NA NA 2019 NA NA *Rett til innsyn i logg tr\u00e5dte i kraft med b) 2015 Ja Ja 2016 Ja Nei 2017 Ja Ja 2018 Ja Ja 2019 Ja Ja Kommentarer: a) Norsk abortstatistikk: tjenestene 2015 Ja Nei Nei Nei 2016 Ja Nei Nei Nei 2017 Ja Ja Ja Ja 2018 Ja Ja Ja Ja 2019 Ja Ja Ja Ja Kommentarer: a) Kvalitetsindikatorer fra Abortregisteret 1 2019 0 *Endelige tall publiseres et al. Childbirth or termination of pregnancy: does paid employment matter? A population study of women in reproductive age in Norway. Acta Obstetricia et Gynecologica Scandinavica, 95 Iversen Implementing medical abortion with mifepristone and misoprostol in Norway 1998 -2013. Int J Epidemiol. 2017;46(2):643 -51. C 2018 Hognert H et al. Ecological study on the use of hormonal contraception, abortions and births among teenagers in the Nordic countries. BMJ Open. 2018 Oct FHI eD\u00c5R fortsatt, 2015 IA 0 52 162 52 162 100,0 % 40 015 40 729 2016 IA 0 43 360 43 360 100,0 % 39 936 40 629 2017 IA 0 51 263 51 263 100,0 % 39 977 40 711 2018 IA 78 56 345 56 423 99,9 % 39 907 40 783 2019 IA 1167 55201 56368 97,9 % IA c) c) Kommentarer: a) I henhold til h elsepersonelloven \u00a7 p\u00e5 > 99 % for bosatte som d\u00f8r i Norge, og > 98 % hendelser, % Usikkerhet d) 2015 40 729 IA IA IA 40 015 98,2 Lav 2016 40 629 IA IA IA 39 936 98,3 Lav 2017 40 711 IA IA IA 39 977 98,2 Lav 2018 40 783 IA IA IA 39 40 629 IA 711 IA Total vurdering av korrekthet g) 2015 Ja Ja Nei Ja Ja Ja Medium/h\u00f8y 2016 Ja Ja Nei Ja Ja Ja Medium/h\u00f8y 2017 Ja Ja Nei Ja Ja Ja Medium/h\u00f8y 2018 Ja Ja Nei Ja Ja Ja Medium/h\u00f8y barn \u00e5r og Kreftregisteret for en del kreftd\u00f8dsfall, s\u00e6rlig opp usannsynlige kontrollprogram, EDIT, som uker/mnd. a) Tid av til 22 31.12.2015 02.11.2016 IA Nei 2016 Uker - Inntil 23 31.12.2016 13.12.2017 IA Uker - Inntil 23 31.12.2017 12.12.2018 IA 2018 Uker - mnd Inntil 23 mnd 31.12.2018 04.12.2019 IA D webbasert statistikkbank 2015 IA Nei Nei Ja 2016 IA Nei Nei Ja 2017 IA Nei Nei Ja 2018 IA Nei Nei Ja 2019 IA Nei Nei Ja Kommentarer: I tillegg til D\u00c5R statistikkbanker ved Folkehelseinstituttet (Norgeshelsa/Kommunehelsa) og hos EUROSTAT og WHO. a) N\u00e6rmeste p\u00e5r\u00f8rende om innsyn . for i D \u00f8ds\u00e5rsaksregisterforskriften, som tr\u00e5dte i kraft i 6 42 7 35 52 98 2016 5 53 1 15 60 94 2017 5 39 1 21 58 77 2018 8 40 7 21 8 85 0 95 2019 2 23 7 65 8 98 0 97 Kommentarer: Periodiske rapporter med data avdeling for rusmidler og tobakk Mortality and population data - WHO D\u00f8ds\u00e5rsaker - NOMESKO Aggregated mortality 2015 31 0 2016 61 0 2017 59 0 2018 81 0 2019 81 0 Kommentarer: Innsynsforesp\u00f8rsler vedr\u00f8rende b) 2015 Ja Ja 2016 Ja Ja 2017 Ja Ja 2018 Ja Ja 2019 Ja Ja Kommentarer: a) Data fra D\u00c5R tjenestene 2015 Ja Nei Nei Nei 2016 Ja Nei Nei Nei 2017 Ja Nei Nei Nei 2018 Ja Nei Nei Nei 2019 Ja Nei Nei Nei Kommentarer: Eurostat, WHO eller Global Burden of Disease. Der det er \u00e5penbart at data fra D\u00c5R har v\u00e6rt brukt i artiklene, er de i tillegg de angitte artiklene tidsskrifter j f. punkt 3-7. 2. Google Scholar s\u00f8ker i HTML og Death Registry (eller Register ) Death Registry at Statistics Norway Death Certificates at the 109 2019 119 *Endelige tall publiseres BH, Haberg SE, Vollset SE. Association of Household Income With Life Expectancy and Cause -Specific Mortality in Norway, 2005 Norge ikke Norge. Forskjellen mellom landene st\u00f8rst for de med lav og middels lav inntekt. For individer i E, Overland S, Egeland GM, Vollset SE, Tell GS. Mortality following first -time hospitalization with acute myocardial infarction in Norway, 2001 -2014: Time trends, underlying causes and place of death. Int J Cardiol. 2019;294:6 -12. d\u00f8ds\u00e5rsaker. C 2019 Sun YQ, Burgess S, Staley JR, Wood AM, Bell S, Kaptoge SK, Guo Q, Bolton TR, Mason AM, Butterworth AS, Di Angelantonio E, Vie GA, Bjorngaard JH, Kinge JM, Chen Y, Mai XM. Body mass index and all cause mortality in HUNT and UK Biobank studies: linear and fra Nord r\u00f8ykere fant man daglig. Modellene som er reduserer sjansen for biases form av reverse causation confounding, noe som gj\u00f8r vedtatt i juni 2019 og som tr\u00e5dte i kraft i oktober 2019, \u00e5 var ved \u00e5rsskiftet tatt i en fagr\u00e5dsmedlemmer. En seniorr\u00e5dgiver og koder gikk i 2019 av med pensjon. Nye 2018 og statistikkbank 2015 Nei Nei Nei Ja 2016 Nei Nei Nei Ja 2017 Nei Nei Nei Ja 2018 Nei Nei Nei Ja 2019 Nei Nei Nei Ja I statistikkbanken finnes statistikk om episoder i basisregisteret fra 3 7 0 2 1 17 87 2016 0 2 1 0 9 7 89 2017 6 4 1 2 4 11 79 2018 0 3 0 0 1 12 0 87 2019 0 1 2 11 2 10 0 83 Tallene i tabell b) 2015 2 0 2016 1 0 2017 11 3 2018 1 1 2019 6 5 Kommentarer: Innsynsforesp\u00f8rsler b) 2015 4 1 2016 1 1 2017 1 1 2018 7 0 2019 7 0 Kommentarer: tjenestene 2015 Nei Nei Nei Ja 2016 Nei Ja Nei Ja 2017 Ja Ja Ja Ja 2018 Ja Ja Ja Ja 2019 Ja Ja Ja Ja Kommentarer: Driftsrapport helseregistrene 2019 Folkehelseinstituttet 4 2019 7 *Endelige tall publiseres Ellekjaer H, Wethal T et al Stroke risk after transient ischemic attack in a Norwegian prospective GS; Forekomst av hjerte in a Norwegian prospective cohort -register: OUS informe rte i 2019 om sagt opp og gikk ut juli ablasjonsbehandling i Norge (AblaNor). Kvalitetssikring data data fra avtalespesialister \u00c5 lage et system datamottak i basisregisteret, og en den vi mars 2019 p\u00e5 Solstrand Hotel & Bad. Faglig m\u00f8te (ca. 50 deltagere) med forskingspresentasjoner fra FHI Oslo og Bergen, St. Olavs Hospital, Haukeland Universitetssjukehus, NTNU, UiB, OUS, UNN, AHUS. prosjektet: \"Incidence, tre of, and survival after cardiac arrest in Norway.\" Hovedsamarbeidspartner: Professor Jo Kramer foreligger for registerdatautviklingsprosjektet: \"Temporal and case -fatality from acute myocardial infarction in Norway HUS): after treatment for prostate cancer\". 5 millioner kroner bevilget 90 85 331 2255 87 586 2,6 % 67 982 119731 2016 254 74813 2 468 2 % 69 120126 2017 126 87424 4 152 91 577 4,5 % 66 518 114 904 2018 112 76 067 2 880 78 947 3,6 % 65 150 111 939 Kommentarer: f\u00f8dselsmeldinger fra 1967 og barnemeldinger fra 1999 ble migrert over i et nytt h\u00f8yere 16 tidligere \u00e5r er at alle f\u00f8dselsmeldinger og c) 2015 68 537 67 982 99,2 % 2016 69 854 69 289 99,2 % 2017 67 099 63 263 94,3 % 4 328 66 518 99,1 % 2018 65 802 61 446 93,4 % 3 704 65 150 99,0 % Kommentarer: som overflyttes til nyf\u00f8dt intensiv er derfor bra, men den er mer usikker for barn som til andre barneavdelinger. vet for lav, men har ikke et 2016 fram til i dag mottatt en fil fra Rikshospitalet. Vi er i dialog 2016 69289 2017 66 518 53 248 80 0 % 13 270 66 518 100,0 % 2018 65 150 52 992 81,3 % 12 158 65 150 100,0 % under kvalitetssikring har ikk e tilbakemelding f) Total vurdering av korrekthet g) 2015 Ja 2 Ja Ja Ja Ja Medium 2016 Ja 2 Ja Ja Nei Ja Medium 2017 Ja 2 Ja Ja Ja Ja Medium 2018 Ja 2? Ja Ja Ja Ja Medium Kommentarer: data, dager/ uker/mnd. a) Tid fra mottak av data til I tabellen tiden statistikkbank 2015 Nei Nei Ja Ja 2016 Nei Nei Ja Ja 2017 Nei Nei Ja Ja 2018 Ja Nei Ja Ja 2019 Ja Nei Ja Ja Kommentarer: Den enkelte registrerte kan via 46 1 4 6 52 90,0 2016 4 49 2 7 8 53 91,3 2017 6 36 1 1 7 69 85,8 2018 14 39 0 4 6 58 1 90,6 2019 7 30 0 1 6 71 0 88,0 Kommentarer: Periodiske rapporter: 1. Stillbirths for 2. Europeristat 5. Data b) 2015 19 0 2016 27 0 2017 48 3 2018 28 1 2019 18 5 Kommentarer: Innsynsforesp\u00f8rsler innhold fra registeret b) 2015 Ja Ja 2016 Ja Ja 2017 Ja Ja 2018 Ja Ja 2019 Ja Ja Kommentarer: a) Data fra MFR av tjenestene b) 2015 Ja Ja Ja Ja 2016 Ja Ja Ja Ja 2017 Ja Ja Ja Ja 2018 Ja Ja Ja Ja 2019 Ja Ja Ja Ja Kommentarer: Driftsrapport helseregistrene 2019 Folkehelseinstituttet 50 a) Data inkludert i databasen til Den norske mor, far og barn - unders\u00f8kelsen (MoBa) , og er 2. Google scholar Her m\u00e5 man alts\u00e5 publikasjoner: Magnus P. et al. Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol. 2016;45(2):382 -8. Magnus P. et al. Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). Int Epidemiol. 2006;35(5):1146 162 2019 152 *Endelige tall publiseres KG, Hov L, Markestad T. Survival and Impairment of Extremely Premature Infants: uke i 25 enn for de som ble f\u00f8dt senere. B 2019 Markovitz AR, Stuart JJ, Horn Rimm Romundstad PR, Rich -Edwards JW, Asvold BO. Does pregnancy complication history improve cardiovascular disease risk prediction? Find ings from the HUNT study in Norway. Eur Heart J. 2019;40(14):1113 - 20. MC, Haberg SE, Ball S, Malacova E, Nassar N, Leonard H, Pereira G. Association between interpregnancy interval and adverse birth outcomes in women with a previous stillbirth: an international cohort study. Det i inndelt i ulike sykdomsgrupper; A og C. Gruppe B er med april -9. I det i 2019 7 1 meldingspliktige sykdommer gruppe -sykdommer til gruppe A. Fra juni 2019 ble Shewanellainfeksjon og Vibrioinfeksjon nye meldingspliktige sykdommer. Fra 2019 sykdommene gonor\u00e9, H en fil. F\u00f8rste som rappor teres i driftsrapport for 201 9. Tidligere sykdommer rapporteres enda for seg, da til Antall sendes 15 118 15 118 100 % Laboratorier 16 286* 4 071* 20 357 ~ 20 % Referanse - Laboratorier 3 438 66 3 504 ~ 2 % Totalt gruppe A 19 724 19 225 38 979 ~ 49 % 20 504 18 804 Tub- beh. Behandlings - resultat 0 51 51 Tub- beh. Forebyggende behandling 0 466 466 100 % 466 466 Totalt tub - beh. 0 517 517 100 % 517 SOI Kliniker 0 1 462 1 462 100 % Laboratorier 1 650 412 2 062 20 % Totalt SOI 1 650 1 874 3 524 100 % 2082 1 394** Gruppe C Gen. Klamydia *2018 Laboratorier 17 26 570 0 % 26 570 IA HPV Endelige tilfeller 623 623 0 % er n\u00e6r 100 c) Gruppe A Kliniker Ingen estimat 20 504 IA 0 20 504 IA Medium Lab. Tub. beh.res. Kliniker 169 51 118 169 ~100 % Lav Ingen estimat 2 082 IA 0 2 082 Medium Lab. Gen. klamydi a 2018 Lab. Ingen estimat 26 570 IA 0 IA IA Lav Kommentarer : a) En 2020. I C vil % c) Gruppe A 20 504 IA IA 9 986 IA IA SOI 2 080 ~60 % 100 % Gruppe C Gen. Klamydia *2018 26 570 26 570 ~100 relevant *For via telefon. C Smittevei 71 % Tuberkulose F\u00f8dselsnummer 95 % Gruppe A F\u00f8dselsnummer % sykdommene i sykdommer som er meldingspliktig e, i For gruppe vil dekningsgraden avhenge av hvor for 201 f) Total vurdering av korrekthet g) Gruppe A Ja Nei Nei Ja Delvis Nei H\u00f8y SOI Nei/Ja IA Nei Ja Nei/delvis Nei Ja Kommentarer : a) Meldingene for SOI f\u00f8r 2019 og genital klamydia for uker/ mnd. a) Usikkert Kommentarer : gruppe vil \u00e5rgangen v\u00e6re klar 201 webbasert statistikkbank 2015 Nei Nei Nei Ja 2016 Nei Nei Nei Ja 2017 Nei Nei Nei Ja 2018 Nei Nei Nei Ja 2019 Nei Nei Nei Ja 1 1 5 5 34 100 % 2016 1 3 7 2 42 100 % 2017 0 2 6 1 43 100 % 2018 0 1 1 4 38 1 100 % 2019 0 1 1 7 25 1 100 % Kommentarer : a) Statistiske data fra MSIS 2015 0 0 2016 1 1 2017 10 1 2018 3 2 2019 8 7 Kommentarer: Innsynsforesp\u00f8rsler fra antall b) 2015 7 8 2016 9 8 2017 6 39 2018 7 56 2019 5 8 Kommentarer : a) \u00c5rsrapporter og andre rapporter publisert med data fra MSIS, publisert i 201 gikk ned. a. Barnevaksinasjonsprogrammet i Norge. Overv\u00e5kning av seksuelt overf\u00f8rbare infeksjoner sykdommer. \u00c5rsrapport 201 8. d. Tuberkulose i Norge 201 8 - med behandlingsresultater for 201 International Circumpolar Surveillance, som publiseres sammen med tall fra andre land ulike 2015 Nei Nei Nei Ikke relevant 2016 Nei Nei Nei Ikke relevant 2017 Nei Nei Nei Ikke relevant 2018 Nei Nei Nei Ikke relevant 2019 Nei Nei Nei 2016 9 12 2019 11 *Endelige tall publiseres Lange H, Feruglio S, Vold L, MacDonald E. Evaluation of the national surveillance of Legionnaires' disease in Norway, 2008 for kvalitetssikring av kompletthet B 2019 Winje BA, Groneng GM, White RA, Akre P, Aavitsland P, Heldal E. Immigrant screening for latent tuberculosis infection: Numbers needed to test and treat, a Norwegian population -based cohort study. BMJ Open 2019;9 (1) (no pagination)(e023412). https://www.ncbi.nlm.nih.gov/pubmed/30782706 al. Livestock -Associated MRSA CC1 in Norway; Introduction to Pig Farms, Zoonotic and Eradication. Frontiers in Microbiology 2019;10 Lange H, Feruglio S, Vold L, MacDonald E. Evaluation of the national surveillance of Legionnaires' disease in Norway, 2008 -2017. BMC public health 2019;19(1):1624. Abstract: BACKGROUND: In Norway, Legionnaires' disease is reportable upon clinical suspicion to public health authorities and mandatorily notifiable through the Norwegian surveillance system for communicable diseases (MSIS) for both clinicians and laboratories. In the summer of 2017, several European countries reported high notification rates for Legionnaires' disease, which was not observed in Norway. We evaluated MSIS to assess if it meets its objectives of detecting cases and trends in incidence of Legionnaires' disease. METHOD(S): We retrieved MSIS data from 2008 to 2017 and calculat ed timeliness as days from sampling to notification, and internal completeness for key variables as the proportion of observations with a value. Where possible, we assessed internal validity on the presence of a plausible value. To estimate external comple teness and validity we linked MSIS with hospital reimbursement claims in the Norwegian Patient Registry. To assess acceptability and representativeness, we surveyed doctors in 39 hospitals on their units' diagnostic and notification procedures, and their u se of MSIS. RESULT(S): There were 438 notified cases. Internal completeness and internal validity were high for key variables (>=95%). The median delay from sampling to notification was 4days. There were 73 patients in MSIS only, 70 in the Norwegian Patien t Registry only, and 351 in both registers. The external completeness of MSIS was 83% (95% CI 80 -86%). For external validity, the positive predictive value of MSIS was 83% (95% CI 79 -86%). Forty -seven respondents from 28 hospitals described testing procedu res. These were inconsistent: 29 (62%) reported no systematic application of criteria for requesting legionella testing. Eighteen (38%) reported testing all patients with suspected pneumonia and a travel history. Thirty -one (66%) found the notification cri teria clear. CONCLUSION(S): Our results suggest that the surveillance in MSIS can detect incidence changes for Legionnaires' disease over time, by place and person, but likely does not detect every case diagnosed in Norway. We recommend wider investigation of diagnostic procedures in order to improve representativeness and awareness of MSIS notification criteria among clinicians in order to improve acceptability of the surveillance. We also recommend a more comprehensive assessment of whether patients only registered in the Norwegian Patient Registry were true Legionnaires' disease cases. Publikasjon B Winje BA, Groneng GM, White RA, Akre P, Aavitsland P, Heldal E. Immigrant screening for latent tuberculosis infection: Numbers needed to test and treat, a Norwegian population -based cohort study. BMJ Open 2019;9 (1) (no pagination)(e023412). Abstract: Objectives To estimate the number needed to screen (NNS) and the number needed to treat (NNT) to prevent one tuberculosis (TB) case in the Norwegian immigrant latent tuberculosis infection (LTBI) screening programme and to explore the effect of delay of LTBI treatment initiation. Design Population - based, prospective cohort study. Participants Immigrants to Norway. Outcome Incident TB. Methods We obtained aggregated data on immigration to Norway in 2008 -2011 and used data from the Norwegian Surveillance System for Infectious Diseases to assess the number of TB cases arising in this cohort within 5 years after arrival. We calculated the average NNS and NNT for immigrants from the top 10 source countries for TB in Norway and by estimated TB incidence rates in sour ce countries. We explored the sensitivity of these estimates with regard to test performance, treatment efficacy and treatment adherence using an extreme value approach, and assessed the effects of emigration, time to TB diagnosis (to define incident TB) a nd intervention timing. Results NNS and NNT were overall high, with substantial variation. NNT showed numerically stronger negative correlation with TB notification rate in Norway ( -0.75 [95% CI - 1.00 to -0.44]) -0.32 [95% CI -0.93 to 0.29]). NNT was affected substantially by emigration and the definition of incident TB. Estimates were lowest for Somali (NNS 99 [70-150], NNT 27 [19 -41]) and highest for [413 -887], NNT 111 [79 -116]). Implementing LTBI treatment in immigrants sooner after arrival may improve the effectiveness of the programme. Conclusion Using TB notifications in Norway, rather than IR in source countries, would improve targeting of immigrants for LTBI management. However, the over all high NNT is a concern and challenges the scale -up of preventive LTBI treatment for significant public health impact. Better data are urgently needed to monitor and evaluate NNS and NNT in countries implementing LTBI screening. Driftsrapport al. Livestock -Associated MRSA CC1 in Norway; Introduction to Pig Farms, Zoonotic Transmission, and Eradication. Frontiers in Microbiology 2019;10 (FEB) (no pagination)(139). Abstract: Farm animals have been identified as an emerging reservoir for transmission of livestock - associated methicillin -resistant Staphylococcus aureus (LA -MRSA) to humans. The low incidence of MRSA in humans and farm animals in Norway has led to the implementati on of a national strategy of surveillance and control of LA -MRSA aiming to prevent livestock becoming a domestic source of MRSA to humans. In 2015, MRSA clonal complex 1 spa -type t177 was identified in nine Norwegian pig herds in two neighboring counties. An outbreak investigation was undertaken, and measures of control through eradication were imposed. We performed a register -based cohort study including pig herds and MRSA -positive persons in Norway between 2008 and 2016 to investigate the livestock -associ ation of MRSA CC1, the transmission of the outbreak strain to humans before and after control measures, and the effect of control measures imposed. Data from the Norwegian Surveillance System of Communicable Diseases were merged with data collected through outbreak investigations for LA -MRSA, the National Registry and the Norwegian Register for Health Personnel. Whole -genome sequencing was performed on isolates from livestock and humans identified through contact tracing, in addition to t177 and t127 isolat es diagnosed in persons in the same counties. It is likely that a farm worker introduced MRSA CC1 to a sow farm, and further transmission to eight fattening pig farms through trade of live pigs confirmed the potential for livestock association of this MRSA type. The outbreak strain formed a distinct phylogenetic cluster which in addition to the pig farms included one sheep herd and five exposed persons. None of the investigated isolates from possible cases without direct contact to the MRSA positive farms w ere phylogenetically related to the outbreak strain. Moreover, isolates of t177 or t127 from healthcare and community -acquired cases were not closely related to the outbreak cluster. Eradication measures imposed were effective in eliminating MRSA t177 from the positive pig holdings, and the outbreak strain was not detected in the national pig population or in persons from these counties after control measures. Driftsrapport helseregistrene 2019 Folkehelseinstituttet 68 f gruppe C -sykdommene og genital klamydia ble omgjort til 22. mars denne gruppe B -sykdommene \u00a7 4 forskriftsendring for ble meldingspliktig til \u00f8kte kodeoppgaver. Utviklingsoppgaver duplikatsjekk import fil til MSIS. I ca. % av laboratoriemeldingene meldt til vil starte gikk inn i har for 2018 2. Tetanus Annual Epidemiological Report for 2017 3. Diphtheria Annual Epidemiological Report for 2017 4. Hepatitis B Annual Epidemiological Report for 2017 5. Invasive pneumococcal disease Annual Epidemiological Report for 2017 6. Invasive meningococcal disease Annual Epidemiological Report for 2017 7. Haemophilus influenzae Annual Epidemiological Report U, Kacelnik O. Targeting TB or MRSA in Norwegian municipalities during 'the refugee crisis' of 2015: a framework for priority setting in screening. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease E, Hegstad K, Samuelsen O, Enger H, Kacelnik O. The fight to keep resistance at bay, epidemiology of carbapenemase producing organisms (CPOs), vancomycin resistant enterococci (VRE) an d methicillin resistant Staphylococcus aureus (MRSA) in Norway, 2006 - 2017. PLoS ONE 2019;14 C, al. Livestock -Associated MRSA CC1 in Norway; Introduction to Pig Farms, Zoonotic Transmission, and Eradication. Frontiers in Microbiology 2019;10 (FEB) (no pagination)( 139). 4. Jenssen GR, Veneti L, Lange H, Naseer of multiplex PCR diagnostics for gastrointestinal pathogens link ed to increase of notified Shiga toxin -producing Escherichia coli cases in Norway, 2007 -2017. European Journal of Clinical Microbiology and Infectious Diseases 2019;38(4):801 -9. 5. MacDonald E, White R, Mexia R, Bruun T, Kapperud G, Brandal LT, et al. The ro le of domestic reservoirs in domestically acquired Salmonella infections in Norway: Epidemiology of salmonellosis, 2000 -2015, and results of a national prospective case -control study, 2010 -2012. Epidemiology and Infection Stene -Johansen K. Molecular epidemiology of hepatitis B virus infection in Norway. BMC Infect Dis 2019;19 (1) (no pagination)( RA, Odsbu I, Brantsaeter AB, Vestrheim DF. Indirect effects of pneumococcal childhood vaccination in individuals treated with immunosuppressive drugs in ambulatory care: A case -cohort study. Clin Infect Dis 2019;68(8):1367 Hungnes O, N\u00e6ss LM, et al . Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with selfreported severity and duration of illness. Influenza and Other Respiratory Viruses 2019;13(2):191 -200. 9. Winje BA, Groneng GM, White RA, Akre P, Aavitsland P, Heldal E. Immigrant screening for latent tuberculosis infection: Numbers needed to test and treat, a Norwegian population -based cohort study. BMJ Open 2019;9 (1) (no pagination)( e023412). 10. Wolff C, Lange H, Feruglio S, Vold L, M acDonald E. Evaluation of the national surveillance of Legionnaires' disease in Norway, 2008 -2017. BMC public health 2019;19(1):1624. Siira H, Brandal LT. Whole genome sequencing of Salmonella Chester reveals geographically distinct clusters, Norway, 2000 to 2016. Euro Surveill 2019;24(4). Driftsrapport 83,0 % 1 545 492 741 747 Papir 175 396 10,0 % 175 396 121 723 Fil 22 134 337 7,0 % 134 337 57 642 2016 ebXM L 1788 1 887 802 2 134 716 88,5 % 1 887 802 913 419 Papir 136622 6,5 % 136 622 92 910 Fil 34 110 302 5,0 % 110 302 52 897 2017 ebXM L 2081 1 961 564 2 220 88,3 % 1 961 564 1 019 573 Papir 135 640 6,1 % 135 640 94 463 Fil 47 123 541 5,6 % 123 541 59 945 2018 ebXML 2397 2 065 749 2 324 629 88,9 % 2 065 749 1 165 072 Papir 120 210 5,2 % 120 210 90 435 Fil 46 138 670 6,0 % 138 670 70 072 2019 ebXML 2658 2 200 506 2 534 116 87,0 % 2 200 506 1 264 837 Papir 162 162 6,0 % 162 162 124 988 Fil * 171 448 7,0 % 171 448 totalt fra 2018 til 2019. *Fil: I 2019 mottok SYSVAK 1400 e -posthenvendelser med filimport som ble h\u00e5ndtert. 2018 var % Usikkerhet c) 2015 1 855 225 100 Lav 2016 2 134 726 100 Lav 2017 2 220 745 100 Lav 2018 2 324 629 100 Lav 2019 2 534 116 100 Lav Kommentarer: I SYSVAK kan man alle vaksiner og kan barn ikke er Derimot vet ute i kommunene. (2) Etterregistrering av vaksiner for barn som har sesongen 2019/2020 viser at vi ogs\u00e5 i \u00e5r har en solid grad av innrapportering med 60 % av solgte doser % 2015 1 855 225 100 2016 2 134 726 100 2017 2 220 745 100 2018 2 324 692 100 2019 2 534 116 100 f) Total vurdering av korrekthet g) 2015 Ja Ja Ja Ja H\u00f8y 2016 Ja Ja Ja Ja H\u00f8y 2017 Ja Ja Ja Ja H\u00f8y 2018 Ja Ja Ja Ja H\u00f8y 2019 Ja Ja Ja Ja H\u00f8y Kommentarer: a) 201 at man her ) data bruk NA 0 2016 BVP 201 5 Se 201 5 NA Dekningsstatistikk 2016 2,5 m\u00e5neder 0 data, mnd ) data bruk NA 0 \u00d8vrige vaksiner Se 2015 Se 2015 NA Se 2015 NA 0 2017 BVP Se 201 5 Se 2017. NA 0 \u00d8vrige vaksiner Se 2015 Se 2015 NA Se 2015 NA 0 2018 BVP Se 2015 Se 2015 NA data, mnd ) data bruk f) HPV - - 1 7.november 2018. NA 0 \u00d8vrige vaksiner Se 2015 Se 2015 NA Se 2015 NA 0 \u00d8vrige vaksiner Se 2015 Se 2015 NA Se 2015 NA 0 2019 BVP Se 2015 Se 2015 NA Dekningsstatistikk HPV - - Se 2016 innen 20 .november 2019. NA 0 \u00d8vrige vaksiner Se 2015 Se 2015 NA Se 2015 NA 0 Kommentarer: Aktualitetss tatus SYSVAK 1400 e -posthenvendelser med filimport som ble h\u00e5ndtert. I 2018 var antall e - posthenvendelser med filimport for de for foreg\u00e5r i 18 til 2019. 210 757 798* Ja Ikke aktuelt mars 2018. Kommentarer: a) Tall er hentet lokalt. og med var det ikke tilgjengeliggjort for 2015 125 64 6 100 % 2016 65 94 7 100 % 2017 65 114 8 99 % 2018 74 87 1 2019 71 137 1 7 99 % Kommentarer: Driftsrapport helseregistrene 2019 -polio og WHO - og rubella, Venice 0 2016 618 0 2017 759 2 2018 603 1 2019 365 i alle hatt vaksinasjonskort for ungdom mellom 16 og 18 \u00e5r p\u00e5 % 2018. sees spesielt lansert i Dette er en \u00f8kning p\u00e5 130 b) 2015 2 4 2016 3 4 2017 4 4 2018 0 0 2019 3 4 Kommentarer: Se kapittel Ja Ikke relevant Ja Ja 2016 Ja Ikke relevant Ja Ja 2017 Ja Ikke relevant Ja Ja 2018 Ja Ikke relevant Ja Ja 2019 Ja Ikke relevant Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non -Indexed Citations, Daily and Versions(R) 1946 to February 03, 2020, PsycINFO 1806 to January Week 4 2020 Dato : 1 1 ((vaccin? adj3 (surveillance* or register or registry or record*)).tw,kw. 20304 2 SYSVAK.tw,kw. 13 Driftsrapport helseregistrene 2019 Folkehelseinstituttet or 2 20312 4 (norway* or norwegian*).tw,kw. 108400 5 3 and 4 32 6 5 not (conference abstract* or letter* or editorial*).pt. 29 7 limit 6 to yr=\"201 9\" 1 Database: Web of Science (core collection) Dato : 04.02.2020 Antall treff : 2 OR registry OR registries OR database OR record* 5520 3 #1 AND #2 51 4 sysvak* norway* surveillance? OR register OR OR OR database OR record?)) \u00c5R:20 19 (((vaksine? AH, Waalen K, Hungnes O, Naess LM, et al. Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with self-reported severity and duration of illness. Influenza and Other Respiratory Viruses 2019;13(2):191 -200. B 2019 Enerly E, Flingtorp R, Christiansen IK, Campbell S, Hansen M, Myklebust TA. Erratum: An observational study comparing HPV prevalence and type distribution between HPV -vaccinated and -unvaccinated girls after introduction of school - based HPV vaccination in Norway (PLOS ONE (2019) Intussusception among o rotavirus vaccination? Vaccine 2019;37(38):5717 -23. Kommentarer: Publikasjon A BACKGROUND: A population -based pregnancy cohort was established in Norway to study potential effects of exposure to the 2009 influenza pandemic or pandemic vaccination during pregnancy. OBJECTIVES: We studied maternal A(H1N1)pdm09 -specific hemagglutination inhibition (HI) -titer levels and waning in women with influenza -like illness (ILI) in pregnancy compared to vaccinated women. Moreover, we studied the association bet ween HI -titers and self -reported severity and duration of ILI. METHODS: HI-titers against the pandemic virus were measured in maternal blood samples obtained at birth, 3 -9 months after exposure, and linked with information about pregnancy, influenza and v accination from national registries and a cohort questionnaire. RESULTS: Among 1821 pregnant women included, 43.7% were unvaccinated and 19.3% of these had ILI. HI -titers were low (geometric mean titer (GMT) 11.3) in the unvaccinated women with ILI. Highe r HI-titers (GMT 37.8) were measured in the vaccinated women. Estimated HI -titer waning was similar for vaccinated women and women with ILI. Most ILI episodes were Driftsrapport helseregistrene 2019 Folkehelseinstituttet 87 moderate and lasted 3 -5 days. Women with ILI reporting specific influenza symptoms such as fever or cough had higher HI -titers than women without these symptoms. Women who reported being \"very ill\" or illness duration of >5 days had higher HI -titers than women reporting less severe illness or illness of shorter duration, respectively. CONCLUSION S: Antibody waning was similar in vaccinated women and women with ILI. More severe ILI or longer duration of illness was associated with higher HI -titers. Most unvaccinated pregnant women with ILI had low HI -titers, probably due to moderate illness and HI -titer waning between exposure and sampling. Publikasjon B BACKGROUND: Many countries have initiated school -based human papillomavirus (HPV) vaccination programs. The real -life effectiveness of HPV vaccines has become increasingly evident, especially among girls vaccinated before HPV exposure in countries with high vaccine uptake. In 2009, Norway initiated a school -based HPV vaccination program for 12 -year -old girls using the quadrivalent HPV vaccine (Gardasil\u00ae), which targets HPV6, 11, 16, and 18. Here, we aim to assess type -specific vaginal and oral HPV prevalence in vaccinated compared with unvaccinated girls in the first birth cohort eligible for school -based vaccination (born in 1997). METHODS: This observational, cross -sectional study measured the HPV prevalence ratio (PR) between vaccinated and unvaccinated girls in Norway. Facebook advertisement was used to recruit participants and disseminate information about the study. Participants self -sampled vaginal and oral specimens using an Evalyn\u00ae Brush and a FLOQSwab, respectively. Sexual behavior was ascertained through a short questionnaire. RESULTS: Among the 312 participants, 239 (76.6%) had received at least one dose of HPV vaccine prior to sexual debut. 39.1% of vaginal samples were positive for any HPV type, with similar prevalence among vaccinated and unvaccinated girls (38.5% vs 41.1%, PR: For vaccine -targeted types there was some evidence of lower prevalence in the vaccinated (0.4%) compared to t he unvaccinated (6.8%) group (PR: 0.06, 95%CI: 0.01 -0.52). This difference remained adjusting for sexual behavior (PR: 0.04, 95%CI: 0.00 -0.42). Only four oral samples were positive for any HPV type, and all of these participants had received at least one dose of HPV vaccine at least 1 year before oral sexual debut. CONCLUSION: There is evidence of a lower prevalence of vaccine -targeted HPV types in the vagina of vaccinated girls from the first birth cohort eligible for school -based HPV vaccination in Norway; this was not the case when considering all HPV types or types not included in the quadrivalent HPV vaccine. Publikasjon C BACKGROUND: To reduce the risk of vaccine -associated intussusception, rotavirus vaccination in Norway was implemented under strict age limits (the first dose given by 12weeks of age and the second dose by 16weeks of age) in 2014. We estimated the incidence of intussusception in children <2years old before vaccine introduction and the number of vaccine -associated cases under current and extended age limits for vaccine administration in Norway. Driftsrapport helseregistrene 2019 Folkehelseinstituttet 88 METHODS: To estimate the baseline incidence, we validated all diagnoses in children <2years old registered in the national hospital registry during the pre -vaccine period of 2008 -2013. Using national vaccine coverage data and international estimates of intussusception risk after rotavirus vaccination, we calculated the numbers of expected vaccine - associated intussusception cases to compare with the estimated numbers of averted rotavirus cases. Uncertainty was accounted for by several scenario analyses using current and extended age limits for vaccine administration. RESULTS: The pre -vaccine incidence of intussusception was 26.7 (95% CI 23.1 -30.6) per 100,000 and CI 31.2 -43.8) cases/year per 100,000 children <1year old. In the 2016 birth cohort (approx. 60,000) vaccinated under the current age limits, 1.3 (95% CI 0.7 -2.0) vaccine -associated intussusception cases were expected to occur. If age limi ts were extended to 16weeks for the first vaccine dose and 24weeks for the second dose, leading to more children vaccinated at an older age, 2.2 (95% CI 1.2 -3.5) excess cases would be expected in the same cohort. Simultaneously, an estimated 1768 rotavir us hospitalizations/year in children <5years old would be averted under current age limits, with 98 additional rotavirus hospitalizations averted under extended age limits. CONCLUSIONS: Administering rotavirus vaccines beyond current age limits in Norway would lead to a marginal increase in the number of intussusception cases, which would be offset by the benefits of vaccination. Driftsrapport helseregistrene 2019 Folkehelseinstituttet 89 SYSVAK \u00d8kningen i e med filimport som ble h\u00e5ndtert. I 2018 var for 2017 og 2018 og det ble rapportert norske tall til WHO (World Health Organization Comm unicable Disease Annual Reporting Form) for 2017 og 2018. Pr 31.12.19 best\u00e5r det data av og inneholder opplysninger kan 2018 NOIS -PIAH infeksjon sykehus d) 123 111 2018 NOIS -PIAH infeksjon sykehjem 1 062 0 1062 49 606 2018 NOIS -PIAH antibiotika sykehus d) -PIAH antibiotika data fra 1. og 2. tertial 2019. Leveringsfrist for 3. tertial er melding batch. En batch inneholder data om flere data 1. og 2. tertial 2019. Leveringsfrist for 3. tertial er Total i helseinstitusjo nene Valideringsmot or i dataverkt\u00f8y tar mesteparten, vi manuell kontroll. for logiske opp lokalt er p\u00e5 begge registre (jf. artikkel: The quality of denominator data in surgical site infection surveillance versus administrative data in Norway 2005 -2010). egne data. Frist for a) Tid til 6 6 IA 100 NOIS PIAH sykehjem IA IA 1 IA 6 18 IA 100 NOIS POSI IA IA 2 IA 49 1 IA 100 2018 NOIS PIAH sykehus IA IA 4 IA 9 8 IA 100 NOIS PIAH sykehjem IA IA 0 IA 7 19 IA 100 NOIS POSI IA IA 5 IA 72 1 IA 100 2019 NOIS PIAH sykehus IA IA 4 IA 9 3 IA 100 NOIS PIAH sykehjem IA IA 2 IA 6 10 IA 100 NOIS POSI IA IA 1 IA 66 2 IA data 2014 0 2015 2 2016 1 2017 4 2018 3 2019 1? *Endelige tall E. P. Astagneau, M. Aupee, M. A. H.J. Choi, S.C. Greeff, Elgohari, Gastmeier, R. McCann, I. Prantner, E. Presterl, M. Pujol, J. Reilly, C. Roberts, L. Segagni Lusignani, D. Si, E. Szil\u00e1gyi, J. Tanguy, S. Tempone, N. Troillet, L.J. Worth, D. Pittet, S. Harbarth, Impact of participation in a surgical site infection surveillance network: results from a large international cohort study, Journal of Hospital Infection, Volume 102, Issue 3, 2019, Pages 267 - Kommentarer: Publisering A In this large, international cohort study, pooled SSI rates were associated with a stable and sustainable decrease after joining an SSI surveillance network; a causal relationship is possible, although unproven. There was heterogeneity in procedure -specific trends. These findings support the pivotal role of surveillance in reducing infection rates and call for widespread implementation of hospital -based SSI surveillance in high -income countries. I 2018 019 har vi derfor utviklet og lansert resultatrapporter er planlagt rapportering Antimicrobial Resistance Surveillance Network, EARS -NET, ved ECDC og The Global Antimicrobial Resistance Surveillance System, GLASS, ved Den internasjonale og WHO og laster opp data i hhv The European Surveillance System (TESSy) og GLASS IT Platform. 718 22 diagnostiske laboratorier 11 nasjonale referanse - laboratorier 14 849 IA 14 849 IA 14 849 IA 2017 22 diagnostiske laboratorier 13 242 IA 13 242 IA 13 242 652 22 diagnostiske laboratorier 11 nasjonale referanse - laboratorier Ca 12 000 IA Ca 12 000 IA Ca 12 000 IA Kommentarer: a) Innregistrering av data fra laboratoriene i % Usikkerhet c) 2015 IA IA IA IA IA IA IA 2016 IA IA IA IA IA IA IA 2017 IA IA IA IA IA IA IA 2018 IA IA IA IA IA IA IA 2019 IA IA IA IA IA IA IA Kommentarer: Laboratoriene registrerer vi har ingen holdepunkter for at det e i NORM Data i NORM kommentar kommentar 13 718 14 Se kommentar Se kommentar 14 849 100% 2017 13 Se kommentar Se kommentar Se kommentar 242 100% 2018 Se kommentar Se kommentar 11 652 100% Ca 12 000 Se kommentar Ca -sentralen l\u00f8pende dialog sender f) Total vurdering av korrekthet g) 2015 IA IA IA Ja Ja Ja H\u00f8y 2016 IA IA IA Ja Ja Ja H\u00f8y 2017 IA IA IA Ja Ja Ja H\u00f8y 2018 IA IA IA Ja Ja Ja H\u00f8y 2019 IA IA IA Ja Ja Ja H\u00f8y Kommentarer: h) NORM samt v ed referanselaboratoriene. Korrekthet uker/mnd. a) Tid mottak av data til bruk og dager/uker /mnd. f) 2015 IA Januar 2016 September 2016 Ca 7 m\u00e5neder Ikke avvik 2016 Ikke avvik 2018 2019 Juni m\u00e5neder Ikke avvik 2019 IA til data fra prosjekter som ikke er med i de kontinuerlige i webbasert statistikkbank 2015 IA IA IA IA 2016 IA IA IA IA 2017 IA IA IA IA 2018 IA IA IA IA 2019 IA IA IA IA Kommentarer: NORM IA 1 IA 1 IA IA 100% 2016 IA IA 2 IA 1 IA IA 100% 2017 IA IA 3 IA 1 IA IA 100% 2018 IA IA 3 IA 1 IA IA 100% 2019 IA IA 2 IA 1 IA IA 100% Kommentarer: NORM -sentralen har Network, EARS -NET\u00bb og \u00abWHO - Global Antimicrobial Resistance Surveillance System, GLASS \u00bb der data for antibiotikaresistens i kliniske bakterieisolater i Norge sammenstilles med til svarende 2015 IA IA 2016 IA IA 2017 IA IA 2018 IA IA 2019 IA IA b) 2015 1 1 2016 1 1 2017 1 2 2018 1 2 2019 1 2 Kommentarer: a) \u00c5rlig rapport NORM /NORM \u00abEuropean data for antibiotikaresistens i kliniske bakterieisolater i Norge sammenstilles med Global Resistance Surveillance System, GLASS\u00bb som er et WHO -initiativ for global overv\u00e5king tjenestene 2015 IA IA Ja Ja 2016 IA IA Ja Ja 2017 IA IA Ja Ja 2018 IA IA Ja Ja 2019 IA IA Ja Ja Kommentarer: NORM st\u00f8tter \u00abRegjeringens publikasjoner der ansatt er forfatter eller del tall publiseres G, J, A, Rossolini GM, van de -Bruinsma emlikov\u00e1 H, Monnet DL, Simonsen GS; Ears -Net Participants. Strong correlation between the rates of intrinsically antibiotic -resistant species and the rates of acquired resistance in Gram -negative species causing bacteraemia, GS, Sollid JUE, Furberg AS. Hormonal contraceptive use and Staphylococcus aureus nasal and throat carriage in a Norwegian youth population. PLoS One. 2019 Jul between the rates of intrinsically antibiotic -resistant species and the rates of acquired resistance in Gram -negative species causing bacteraemia, EU/EEA, iboende resistens. B) Stensen et al. Hormonal contraceptive use and Staphylococcus aureus nasal and throat carriage in a Norwegian youth population. Staphylococcus aureus er viktig \u00e5rsak til alvorlige infeksjoner og S. hos 439 jenter i alderen 17 - 21 \u00e5r i av ny funksjonalitet knyttet til import og eksport av data til og fra eNORM. NORM sentralen har ledet utvikling og pilotering av ny funksjonalitet knyttet til import og eksport av data til og fra eNORM. Uttrekk og overf\u00f8ring av basisdata fra formaliteter knyttet av NORM personvern og at (RAVN) 12.1 Datamottak og bearbeiding RAVN (Resistensoverv\u00e5king av virus i Norge) er et landsomfattende system for overv\u00e5king av resistens hos virus Avidentifiserte opplysninger om pr\u00f8ver for RAVN ble i 2019 for alle virus som inng\u00e5r overv\u00e5kningen 2019, 0 5 0 959 Ikke aktuelt 2016 4 5 0 5 0 813 Ikke aktuelt 2017 4 5 0 5 0 650 Ikke aktuelt 2018 4 5 0 5 0 793 2019 Data ikke for samlet og HSV i tillegg en fastafil virus b) En hendelse i RAVN vil v\u00e6re ett virus (fra en p asientpr\u00f8ve) unders\u00f8kt for antiviral resistens. Ett hiv i Norge er tidligere diagnostisert i andre land, har startet IT behov for revisjon av Total vurdering av korrekthet g) 2015 nei nei nei ja nei Nei h\u00f8y 2016 nei nei nei ja nei Nei h\u00f8y 2017 nei nei nei ja nei Nei h\u00f8y 2018 nei nei nei ja nei Nei h\u00f8y 2019 Data ikke mottatt enn\u00e5 til andre register er ikke mulig. b) RAVN er et avidentifisert register c) RAVN er et avidentifisert register d) I uker/mnd. a) Tid av til - kalenderen, dager/uker /mnd. f) 2015 2 - 14 mnd 1 - 6 mnd 31.12.15 (Influensa: uke 20 2016) Sept 2016 17.10.2016 nei 2016 2 - 14 mnd 1- 6 mnd 31.12.16 (Influensa: uke 20 2017) Sept 2017 25.09.2017 nei 2017 2 - 14 mnd 1- 6 mnd 31.12.16 (Influensa: uke 20 2018) Nov 2018 22.11.2018 Ja, 2 mnd 2018 2 - 14 mnd 1- 6 mnd 31.12.16 (Influensa: uke 20 2019) Okt 2019 uke 20 det etterf\u00f8lgende \u00e5r, men pr\u00f8ver tatt 0 4 1 1 0 100% 2018 0 0 0 0 1 1 0 Ikke aktuelt 2019 0 0 0 0 1 1 aktuelt Kommentarer: direkte antall b) 2015 Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2013 -2014 2016 Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2015 2017 Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2016 SPREAD, ESAR 2018 Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2017 2019 Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018 ECDC: HIV-1 transmitted drug resistance in Europe, 2018 Kommentarer: b) Med utgangspunkt i prosjektet \u00abLangtidsstudie av endringer hiv -resistensdata for 2014 - 2016 til overv\u00e5kingsprogrammet SPREAD (Strategy to Control SPREAD of HIV Drug Resistance). SPREAD er underlagt ESAR (European Society for translational Antiviral Research). F.o.m. resistensdata med tjenestene 2015 Nei Nei Ja Ja 2016 Nei Nei Ja Ja 2017 Nei Nei Ja Ja 2018 Nei Nei Ja Ja 2019 Nei Nei Ja Ja Kommentarer: 12.3.3 0 2019 0 *Endelige tall publiseres 840 (801 - 834) 9 818 0 9 818 0 % 47 372 041 3 577 424 2016 873 (837 - 870) 10 234 0 10 234 0 % 49 408 001 3 630 905 2017 904 (871 - 900) 10 631 0 10 631 0 % 51 184 560 3 688 097 2018 941 (902 - 936) 11 031 0 11 031 0 % 52 388 422 3 724 382 2019 973 (940 - 962) 11392 0 11392 0 % 53 897 c) 2015 9 818 9 791 99,72 % 27 9 817 99,99 % Lav 2016 10 234 10 216 99,82 % 18 10 226 99,92 % Lav 2017 10 631 10 613 99,83 % 18 10 630 99,99 % Lav 2018 11 031 11 020 99,90 % 11 11 029 99,98 % Lav 2019 11392 11373 99,83 m\u00e5neder har Folkehelseinstituttet 127 2015 Ca. 52 801 550 Ca. 52 100 650 98,7 % - 52 794 650 99,99 % 2016 Ca. 54 973 532 Ca. 54 360 471 98,9 % - 54 945 294 99,95 % 2017 Ca. 56 850 955 Ca. 56 558 441 99,5 % 18 56 849 380 100,00 % 2018 Ca. 57 897 741 Ca. 57 838 731 99,9 % 11 57 864 441 99,94 % 2019 Ca. 59 381 649 Ca. 57 572 128 96,95 % 19 59 379 Total vurdering av korrekthet g) 2015 Se a) Se b) Nei Ja Ja Nei H\u00f8y 2016 Se a) Se b) Nei Ja Ja Nei H\u00f8y 2017 Se a) Se b) Nei Ja Ja Nei H\u00f8y 2018 Se a) Se b) Nei Ja Ja Nei H\u00f8y 2019 Se a) Se b) Nei Ja Ja uker/mnd. a) Tid av til 12.4.2016 26.4.2016 19.3.2019 26.6.2019 0 dager den i etterf\u00f8lgende m\u00e5ned. b) Data fra Reseptregisteret er tilgjengelig for Folkehelseinstituttet 129 2015 Nei Nei Nei Ja 2016 Nei Nei Nei Ja 2017 Nei Nei Nei Ja 2018 Nei Nei Nei Ja 2019 Nei Nei Nei Ja Reseptregisteret har en ekstern e) 2015 - - 34 49 1 40 Ca. 98 % 2016 - - 37 63 1 53 1 100 % 2017 - - 33 44 1 58 5 99 % 2018 - - 10 45 1 55 1 97 % 2019 - - 21 66 1 69 1 97 % Kommentarer: b) 2015 1 0 2016 1 0 2017 7 3 2018 10 1 2019 13 6 Kommentarer: den b) 2015 3 2016 4 3 2017 5 3 Driftsrapport helseregistrene 2019 Folkehelseinstituttet 131 2018 5 3 2019 4 Kommentarer: a) Samtlige \u00e5r: - \u00c5rlig Antimicrobial Agents and Occurence of Antimicrobial Resistance in Norway in animals and humans\u00bb . 2017: - Rapport om legemiddelbruk hos barn og unge (til HOD) I 2018: - Folkehelserapporten 2018 b) statistiske tjenestene 2015 Ja Nei Ja Ja 2016 Ja Ja Ja Ja 2017 Ja Ja Ja Ja 2018 Ja Ja Ja Ja 2019 Ja Ja Ja Ja Kommentarer: a) Omfattende opplysninger om legemiddelbruk i 2019 brukt et oppdrag fra HOD ble i en til Helsedirektoratet ble d et levert en ny rapport knyttet til et February 05, Ovid MEDLINE(R) and Epub Ahead of Print, In -Process & Other Non -Indexed Citations, Daily and Versions(R) 1946 to February 05, 2020, PsycINFO 1806 to January Week 4 2020 Dato 06.02.2020 : 39 230 2 (prescription* adj3 (surveillance* or or or registries or record*)).tw,kw. 9405 3 (norway* or norwegian*).tw,kw. 108400 4 1 or (2 and 3) 934 5 4 not (conference abstract* or letter* or editorial*).pt. 754 6 limit 5 to yr=\"2019\" 72 7 remove duplicates from 6 39 Database: Web of Science (core collection) Dato : 06.02.2020 Antall treff : 3 #1 OR #2 9 4 surveillance* OR register OR registry OR registries OR database OR record* 5522 5 prescription* OR resept* ((surveillance? register OR registry OR registries OR database OR record?) AND prescription? OR 60 2019 57 *Endelige tall publiseres p\u00e5 E, Dyrkorn R, Spigset O. Effectiveness of an academic detailing intervention in primary care on the prescribing of non -steroidal anti -Data Kaspersen, S.L., Hauge, L.J. & Kalseth, J. 2019. Use of prescription medication prior to suicide in Norway. BMC Health Services Research 19, 215. https://doi.org/10.1186/s12913 -019-4009 -1. fra d\u00f8ds\u00e5rsaksregisteret og reseptregisteret for perioden forskrevne for teknisk personell av Fagpersoner teknisk personell ansatte IT og i forbindelse med kvalitetssikring av dataene i registeret og av data som er utlevert til forskere og andre som s\u00f8ker om alle tillatelser) til utlevering ger for statistikk og individfiler basert p\u00e5 data kun fra Reseptregisteret og 60 dager for data som skal sammenstilles med i fra 2019 stans i ny s\u00f8knader Den statistikk publisert 26. juni 2019. "}